All In Biotech

Drug Trial Radar · NCT06335303

A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

A Randomised, Double-blind, Placebo-controlled, Dose-finding Study Evaluating Efficacy, Safety, and Tolerability of Different Oral Doses of BI 1819479 Over at Least 24 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 322 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

322

Actual

Start

Sep 5, 2024

Primary completion

Nov 25, 2025

Study completion Jan 16, 2026

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Mar 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study. Participants are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1819479. Participants in 1 group get placebo. Placebo tablets look like BI 1819479 tablets, but do not contain any medicine. Participants take the treatment for 6 months to 1 year. Participants are in the study for up to 1 year and 2 months. During this time, they visit the study site between 10 and 12 times and get up to 11 phone calls from the site staff. At site visits doctors regularly perform breathing tests that measure how well the lungs are working. Researchers compare the results between participants who take BI 1819479 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • BI 1819479Drug

    BI 1819479

  • Placebo matching BI 1819479Drug

    Placebo matching BI 1819479

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual rate of decline in Forced Vital Capacity (FVC) [milliLiter/year]Time frame: Up to 52 weeks

Locations

163 sites in 28 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Critical Care, Pulmonary and Sleep Associates

    Lakewood, Colorado

  • Clinical Research Specialists LLC - Kissimmee

    Kissimmee, Florida

  • SEC Clinical Research

    Pensacola, Florida

  • The Iowa Clinic, PC

    West Des Moines, Iowa

  • Advanced Pulmonary Research

    Warren, Michigan

  • Memorial Hospital Gulfport

    Gulfport, Mississippi

  • Coastal Carolina Health Care, P.A. Pulmonary and Sleep Medicine

    New Bern, North Carolina

  • Southeastern Research Center-Winston Salem-69289

    Winston-Salem, North Carolina

  • Clinical Research Associates of Central PA

    DuBois, Pennsylvania

  • Temple University

    Philadelphia, Pennsylvania

  • Lowcountry Lung and Critical Care

    Charleston, South Carolina

  • Spartanburg Medical Research

    Spartanburg, South Carolina

  • Clinical Trials Center of Middle Tennessee, LLC

    Franklin, Tennessee

  • Pulmonary Associates of Richmond, Inc.

    Richmond, Virginia

  • Centro de Investigaciones Metabolicas (CINME)

    C.a.b.a, Argentina

  • Hospital Britanico de Buenos Aires

    CABA, Argentina

  • Centro de Investigación Clinica Belgrano

    CABA, Argentina

  • CEDIC - Centro de Investigacion Clinica

    CABA, Argentina

  • Consultorios Médicos del Buen Ayre

    Capital Federal, Argentina

  • Macquarie University

    Macquarie Park, Australia

  • Canberra Hospital

    Garran, Australian Capital Territory, Australia

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Launceston Respiratory & Sleep Centre

    Launceston, Tasmania, Australia

  • Lung Research Victoria

    Footscray, Victoria, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Institute for Respiratory Health

    Nedlands, Western Australia, Australia

  • Medical University of Graz

    Graz, Austria

  • Krems University Hospital

    Krems, Austria

  • Johannes Kepler University Linz

    Linz, Austria

  • Hospital Elisabethinen Linz

    Linz, Austria

  • Standort Penzing der Klinik Ottakring

    Vienna, Austria

  • Clinic Floridsdorf

    Vienna, Austria

  • Klinikum Wels - Grieskirchen GmbH

    Wels, Austria

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • CHR de la Citadelle

    Liège, Belgium

  • Serviços Medicos Respirar Sul Fluminense

    Barra Mansa, Brazil

  • Faculdade de Medicina de Botucatu - UNESP

    Botucatu, Brazil

  • Hospital das Clínicas da UFG - EBSERH

    Goiânia, Brazil

Showing 40 of 163 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.